Liebers, Nora, Duell, Johannes, Fitzgerald, Donnacha ORCID: 0000-0003-4927-7484, Kerkhoff, Andrea, Noerenberg, Daniel, Kaebisch, Eva ORCID: 0000-0001-7752-4126, Acker, Fabian ORCID: 0000-0002-6207-0237, Fuhrmann, Stephan ORCID: 0000-0002-7785-2565, Leng, Corinna, Welslau, Manfred, Chemnitz, Jens, Middeke, Jan-Moritz, Weber, Thomas, Holtick, Udo, Trappe, Ralf, Pfannes, Roald, Liersch, Ruediger, Spoer, Christian, Fuxius, Stefan, Gebauer, Niklas, Caille, Leandra, Geer, Thomas, Koenecke, Christian, Keller, Ulrich, Claus, Rainer, Mougiakakos, Dimitrios, Mayer, Stephanie, Huettmann, Andreas, Pott, Christiane, Trummer, Arne, Wulf, Gerald, Brunnberg, Uta, Bullinger, Lars ORCID: 0000-0002-5890-5510, Hess, Georg, Mueller-Tidow, Carsten, Glass, Bertram, Lenz, Georg, Dreger, Peter and Dietrich, Sascha (2021). Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv., 5 (13). S. 2707 - 2717. AMSTERDAM: ELSEVIER. ISSN 2473-9537

Full text not available from this repository.

Abstract

The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Liebers, NoraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duell, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fitzgerald, DonnachaUNSPECIFIEDorcid.org/0000-0003-4927-7484UNSPECIFIED
Kerkhoff, AndreaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Noerenberg, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kaebisch, EvaUNSPECIFIEDorcid.org/0000-0001-7752-4126UNSPECIFIED
Acker, FabianUNSPECIFIEDorcid.org/0000-0002-6207-0237UNSPECIFIED
Fuhrmann, StephanUNSPECIFIEDorcid.org/0000-0002-7785-2565UNSPECIFIED
Leng, CorinnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Welslau, ManfredUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chemnitz, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Middeke, Jan-MoritzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weber, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Holtick, UdoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Trappe, RalfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pfannes, RoaldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Liersch, RuedigerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Spoer, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuxius, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gebauer, NiklasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Caille, LeandraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Geer, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Koenecke, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Keller, UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Claus, RainerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mougiakakos, DimitriosUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mayer, StephanieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Huettmann, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pott, ChristianeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Trummer, ArneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wulf, GeraldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brunnberg, UtaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bullinger, LarsUNSPECIFIEDorcid.org/0000-0002-5890-5510UNSPECIFIED
Hess, GeorgUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller-Tidow, CarstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Glass, BertramUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lenz, GeorgUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dreger, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dietrich, SaschaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-606642
DOI: 10.1182/bloodadvances.2020004155
Journal or Publication Title: Blood Adv.
Volume: 5
Number: 13
Page Range: S. 2707 - 2717
Date: 2021
Publisher: ELSEVIER
Place of Publication: AMSTERDAM
ISSN: 2473-9537
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ANTIBODY-DRUG CONJUGATE; NON-HODGKIN-LYMPHOMA; AXICABTAGENE CILOLEUCEL; OUTCOMES; SURVIVALMultiple languages
HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60664

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item